Daljit Singh Aurora Sells 34,987 Shares of Neumora Therapeutics (NASDAQ:NMRA) Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 34,987 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $1.59, for a total transaction of $55,629.33. Following the completion of the transaction, the insider owned 123,660 shares in the company, valued at $196,619.40. The trade was a 22.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Daljit Singh Aurora also recently made the following trade(s):

• On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total value of $51,014.70.
• On Wednesday, August 19th, Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total value of $51,150.00.
• On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total value of $82,524.00.
• On Monday, August 17th, Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total value of $137,535.00.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.58, for a total value of $53,975.96.

Neumora Therapeutics Stock Performance

NASDAQ NMRA remained flat at $1.64 during trading on Wednesday. The company’s stock had a trading volume of 716,090 shares, compared to its average volume of 699,708. Neumora Therapeutics, Inc. has a 52 week low of $0.83 and a 52 week high of $3.65. The business’s 50 day moving average is $1.61 and its 200 day moving average is $2.11. The company has a quick ratio of 5.09, a current ratio of 4.50 and a debt-to-equity ratio of 1.19.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01. On average, equities analysts expect that Neumora Therapeutics, Inc. will post -0.85 EPS for the current year.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NMRA. Siren L.L.C. grew its stake in shares of Neumora Therapeutics by 35.1% in the 1st quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock valued at $16,571,000 after purchasing an additional 2,209,039 shares during the period. BlackRock Inc. bought a new position in shares of Neumora Therapeutics during the 2nd quarter worth approximately $13,246,000. Perceptive Advisors LLC acquired a new stake in Neumora Therapeutics in the 1st quarter valued at $9,953,000. Millennium Management LLC boosted its stake in Neumora Therapeutics by 80.1% in the 4th quarter. Millennium Management LLC now owns 3,616,514 shares of the company’s stock valued at $6,474,000 after buying an additional 1,608,266 shares in the last quarter. Finally, ICONIQ Capital LLC bought a new stake in Neumora Therapeutics in the second quarter valued at $4,350,000. 47.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NMRA has been the topic of several research analyst reports. Mizuho decreased their price target on shares of Neumora Therapeutics from $6.00 to $4.00 and set an “outperform” rating on the stock in a research report on Thursday, June 18th. HC Wainwright reiterated a “buy” rating on shares of Neumora Therapeutics in a research note on Tuesday, July 28th. Weiss Ratings cut Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 14th. Royal Bank Of Canada decreased their price objective on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Wall Street Zen upgraded Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.57.

Neumora Therapeutics News Roundup

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.89 from $1.29 and its FY2027 forecast to a loss of $0.68 from $1.25, indicating analysts expect substantially narrower losses over the next two years.
• Positive Sentiment: The firm also improved its quarterly outlook, forecasting a Q3 2026 loss of $0.20 per share versus $0.32 previously and a Q4 2026 loss of $0.16 versus $0.30 previously.
• Positive Sentiment: Longer-term estimates were upgraded sharply: FY2028’s projected loss narrowed to $0.52 from $1.10, FY2029 moved to projected profit of $0.20 from a $0.26 loss, and FY2030 profit expectations increased to $1.83 from $1.51 per share. These changes imply a faster potential transition to profitability.
• Positive Sentiment: HC Wainwright’s current estimates call for losses of $0.15, $0.16, $0.19 and $0.17 per share in the first four quarters of 2027, respectively, with full-year 2027 losses of $0.68. The firm’s continued Buy rating provides additional support for investor sentiment.
• Neutral Sentiment: Neumora remains unprofitable, with the broader current-year consensus at a loss of $0.93 per share. The company’s shares are trading well below their 200-day moving average and remain near the lower portion of their 12-month range, underscoring continued execution and financing risks despite the improved forecasts.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.